NIH-funded research NIH-funded research

Understanding how genetic changes affect immune responses in squamous cell carcinoma

Official title: Dissecting the genetic basis of cancer immune evasion in squamous cell carcinoma

Funded at University of Chicago · NIH-10990206 · Data updated 2026-11-12

This study is looking at how certain changes in a gene called PIK3CA might help squamous cell carcinoma (a type of cancer) avoid the immune system, and it aims to use this information to make immunotherapy treatments work better for patients like you.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Chicago
NIH-funded
Lab location1 site (Chicago, United States)
Project startSeptember 1, 2024
Project endAugust 31, 2026
Funding year2024
Award (this year)$50,474
NIH project number1F99CA294257-01
Project IDNIH-10990206 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are patients diagnosed with squamous cell carcinoma, particularly those with PIK3CA mutations.

Less likely to help

Patients with other types of cancer or those without squamous cell carcinoma may not benefit from this research.

What this research studies

This research investigates the genetic factors that contribute to immune evasion in squamous cell carcinoma (SCC), a type of cancer that can occur in various parts of the body such as the skin and oral cavity. The study focuses on specific mutations in the PIK3CA gene, which may lead to the development of immune-resistant tumor-initiating cells. By examining how these mutations influence the behavior of cancer cells, the research aims to improve the effectiveness of immunotherapy treatments for patients with SCC. Patients may be involved in the research to help identify genetic markers that predict treatment responses.

Why it matters

Potential benefit: If successful, this research could lead to more personalized and effective immunotherapy options for patients with squamous cell carcinoma.

How similar studies have gone: Previous research has shown promising results in understanding genetic factors in cancer treatment, suggesting that this approach could yield valuable insights.

Where this research is happening

  • University of Chicago
    Chicago, United States
    Active

Researchers

  • Principal investigator: Nicholson, Benjamin — University of Chicago
  • Study coordinator: Nicholson, Benjamin

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.